<DOC>
<DOCNO>EP-0636125</DOCNO> 
<TEXT>
<INVENTION-TITLE>
BASIC DERIVATIVES OF GLUTAMIC ACID AND ASPARTIC ACID AS GASTRIN OR CHOLECYSTOKININ ANTAGONISTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31535	A61K31495	A61K3147	A61K3140	C07D29500	C07D29513	A61P2700	C07D20700	A61P104	C07D40512	A61P100	C07D20709	C07D40100	A61K314427	A61P1306	C07D20714	C07D21500	C07D21706	A61K31495	A61P2702	C07D40500	C07D21554	A61P4300	A61K31435	A61K31443	A61P116	A61K315375	A61P118	A61K31445	A61P2522	A61P2712	C07D29512	A61K3147	A61P4300	A61P2500	C07D29518	A61P1302	A61K31535	C07D295185	C07D22100	C07D22120	C07C23700	C07D21700	A61K314427	A61K31435	A61P2500	A61P1500	A61K315375	C07D45302	C07D40112	C07D45300	A61K31472	A61P1500	A61K3140	A61K31445	A61P100	A61K31472	A61P1300	C07C23722	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	C07D	C07D	A61P	C07D	A61P	C07D	A61P	C07D	C07D	A61K	A61P	C07D	C07D	C07D	A61K	A61P	C07D	C07D	A61P	A61K	A61K	A61P	A61K	A61P	A61K	A61P	A61P	C07D	A61K	A61P	A61P	C07D	A61P	A61K	C07D	C07D	C07D	C07C	C07D	A61K	A61K	A61P	A61P	A61K	C07D	C07D	C07D	A61K	A61P	A61K	A61K	A61P	A61K	A61P	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	C07D295	C07D295	A61P27	C07D207	A61P1	C07D405	A61P1	C07D207	C07D401	A61K31	A61P13	C07D207	C07D215	C07D217	A61K31	A61P27	C07D405	C07D215	A61P43	A61K31	A61K31	A61P1	A61K31	A61P1	A61K31	A61P25	A61P27	C07D295	A61K31	A61P43	A61P25	C07D295	A61P13	A61K31	C07D295	C07D221	C07D221	C07C237	C07D217	A61K31	A61K31	A61P25	A61P15	A61K31	C07D453	C07D401	C07D453	A61K31	A61P15	A61K31	A61K31	A61P1	A61K31	A61P13	C07C237	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of general formula (I), in which r is 1 or 2, R1 is selected independently from: unsubstituted, mono- or di-substituted phenyl groups, unsubstituted, mono- or di-substituted phenylamino groups, the 2(beta)-naphthyl group, and heterocyclic, monocyclic or dicyclic groups; R2 is selected independently from: heterocyclic spiro groups, aminoalkyladamantyl groups, alkylamino groups, C4-C10 cycloalkylamino groups, and dicyclic amino groups (condensed); R3 is H, CH3 or C2H5; A is a bond or a linear or branched alkylene group comprising from 1 to 4 carbon atoms; W is a tertiary amino group or a heterocyclic group.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The subject of the present invention is basic
derivatives of glutamic acid and aspartic acid which
can be represented by the general formula indicated
below:

and in which r is 1 or 2;
R1 is selected independently from:
unsubstituted phenyl; mono- or di-substituted phenyl groups in
which the substituents are selected from the halogens
(chloro, fluoro, and bromo), linear or branched C1-C4
alkyl groups, and nitro, cyano, methoxy, and
trifluoromethyl groups; an unsubstituted phenylamino
group; phenylamino groups mono- or di-substituted as
described above for the phenyl group; the
2(beta)-naphthyl group; heterocyclic, monocyclic
or dicyclic groups selected from an unsubstituted
pyridyl group, pyridyl groups mono- or
di-substituted with methyl, chloro, furyl (2- or 3-yl),
indolyl (2- or 3-yl), isoindolyl (3-yl), benzofuranyl
(2- or 3-yl) quinolinyl (2- or 3-yl) or isoquinolinyl
(3-yl);R2 is selected independently from: 
1) a heterocyclic spiro group represented by:

in which m and n are selected independently and may
have values of between 1 and 3, provided that the ring
formed consists of at least 5 atoms, X and Y are
selected independently from (CH-R4)z, TCH2 and CH2T in
which T is O or S, and in which R4 is a group selected
independently from H, linear and branched C1-C4 alkyl
groups, OCH3, and OH, and z may have values of from 0
to 3, provided that the ring formed consists of at
least 3 atoms;2) an aminoalkyladamantyl group represented by:

in which z and R4 have the meanings given above and Ad
is adamantyl (1- or 2-yl);3) an alkylamino group represented by:

in which R5 is a linear or branched alkyl chain
containing from 4 to 10 carbon atoms or a C5-C10
cycloaklyl group, or a linear or branched alkoxyalkyl
group containing from 4 to 7 carbon atoms, and R6 is
selected independently from H, alkyl groups, linear and 
branched alkoxyalkyl groups containing from 4 to 7
carbon atoms, and C5-C10 cycloalkyl groups;4) a C4-C10 cycloalkylamine;5) a dicyclic amino group (condensed) represented by:

and in which m, n, X, Y, and R4 have the meanings given
above;R3 is H, CH3 or C2H5;A is a bond or a linear or branched alkylene group
comprising from 1 to 4 carbon atoms;W may be:
1) a tertiary amino group represented by:

in which R7 and R8 are, independently, hydrogen or a
linear or branched alkyl group comprising from 1 to 5
carbon atoms, provided that R7 and R8 are not both
hydrogen;2) a heterocyclic group represented by: 

in which R3, m and n have the meanings given above and
Q may be a bond, CH2, oxygen, sulphur
</DESCRIPTION>
<CLAIMS>
Compounds which can be represented by the general
formula indicated below:



and in which r is 1 or 2;

R1 is selected independently from:

unsubstituted phenyl; mono- or di-substituted phenyl groups in
which the substituents are selected from the halogens

(chloro, fluoro, and bromo), linear or branched C
1
-C
4

alkyl groups, nitro, cyano, methoxy, or trifluoromethyl
groups; an unsubstituted phenylamino group; phenylamino

groups mono- or di-substituted as described above for
the phenyl group; the 2(beta)-naphthyl group;

heterocyclic, monocyclic or bicyclic groups selected
from an unsubstituted pyridyl group, pyridyl groups

mono- or di-substituted with methyl, chloro, furyl (2-or
3-yl), indolyl (2- or 3-yl) , isoindolyl (3-yl),

benzofuranyl (2- or 3-yl) quinolinyl (2- or 3-yl) or
isoquinolinyl (3-yl);
R
2
 is selected independently from:

a
1
) a heterocyclic spiro group represented by: 


in which m and n are selected independently and may
have values of between 1 and 3, provided that the ring

formed consists of at least 5 atoms, X and Y are
selected independently from (CH-R
4
)
z
, TCH
2
 and CH
2
T in
which T is O or S, and in which R
4
 is a group selected
independently from H, linear and branched C
1
-C
4
 alkyl
groups, OCH
3
, and OH, and z may have values of from 0
to 3, provided that the ring formed consists of at

least 3 atoms;
b
1
) an aminoalkyladamantyl group represented by:


in which z and R
4
 have the meanings given above and Ad
is adamantyl (1- or 2-yl);
c
1
) an alkylamino group represented by:


in which R
5
 is a linear or branched alkyl chain
containing from 4 to 10 carbon atoms or a C
5
-C
10

cycloaklyl group, or a linear or branched alkoxyalkyl
group containing from 4 to 7 carbon atoms, and R
6
 is
selected independently from H, alkyl groups, linear and

branched alkoxyalkyl groups containing from 4 to 7 
carbon atoms, and C
5
-C
10
 cycloalkyl groups;
d
1
) a C
4
-C
10
 cycloalkylamine;
e
1
) a dicyclic amino group (condensed) represented by:


and in which m, n, X, Y, and R
4
 have the meanings given
above;
R
3
 is H, CH
3
 or C
2
H
5
;
A is a bond or a linear or branched alkylene group
comprising from 1 to 4 carbon atoms;
W may be:

a
2
) a tertiary amino group represented by:


in which R
7
 and R
8
 are, independently, hydrogen or a
linear or branched alkyl group comprising from 1 to 5

carbon atoms, provided that R
7
 and R
8
 are not both
hydrogen;
b
2
) a heterocyclic group represented by: 


in which R
3
, m and n have the meanings given above and
Q may be a bond, CH
2
, oxygen, sulphur or nitrogen,
N-substituted with R
9
, R
9
 being a group selected
independently from H, linear and branched C
1
-C
4
 alkyl
groups, phenyl and benzyl groups, of which the aromatic

groups may be unsubstituted, or mono- or di-substituted
as described for the phenyl group in R
1
;
c
2
) a heterocyclic group represented by:


in which m1 and m2 are selected independently and may
have values of between 0 and 3 and R
3
 and R
9
 have the
meanings given above;
d
2
) a heterocyclic group represented by:


in which m, m1, m2 and R
3
 have the meanings given
above; 
t is always 1, except that in b
2
, when Q is N-R
9
, it
may be 0 or 1, and pharmaceutically acceptable salts thereof.
Compounds according to Claim 1,
in which R
1
 is the 3-chlorophenyl or 3,5-dichlorophenyl
group, R
2
 is selected from the group consisting of
8-azaspiro[4.5]
decano-8-yl or 3-azaspiro[5.5lundecano-3-yl,
t is zero, A is a bond, W is 4-methyl-1-piperazinyl,

r is preferably 2, and R
3
 is hydrogen, and the
stereochemistry of the chiral centre may be racemic (R,

S) or, preferably, R (rectus).
Compounds according to Claim 1,
in which R
2
 is the 3.4-dimethylphenyl or
4-isopropylphenyl group, R
2
 is the dipentylamino group,
-NR
3
A is ethylenamino, W is 4-morpholinyl, r is
preferably 2, and the stereochemistry of the chiral

centre may be racemic (R, S) or, preferably, S
(sinister).
Compounds according to Claim 1,
in which R
1
 is a 3,4-dichlorophenyl, 2-naphthyl or
3-quinolinyl group, R
2
 is the dipentylamino group, A is
a bond or the ethylene group, W is 4-morcholinlyl or

4-methyl-1-piperazinyl, in which case t is zero, r is
preferably 2, and R
3
 is hydrogen, and the
stereochemistry of the chiral centre may be racemic or,

preferably, R (rectus).
A pharmaceutical preparation comprising, as an
active substance, at least one of the compounds

according to Claim 1 or a pharmaceutically acceptable
salt thereof.
A pharmaceutical preparation according to Claim 5 
for use in treatment in dependence on its activity

against ulcers.
A pharmaceutical preparation according to Claim 5
for use in the treatment of tumourous conditions which

are sustained by gastrin or other biologically active
polypeptides related thereto.
A pharmaceutical preparation according to Claim 5
for the treatment of pathological conditions of the CNS

linked to imbalances in the physiological neurone
levels of gastrin or of other biologically active

polypeptides related thereto.
A pharmaceutical preparation according to Claim 5
for use in the treatment of disorders of the- digestive

system due to disturbances of motility and of
mucotrophism such as biliary dyskinesia, colitis and

pancreatitis.
A pharmaceutical preparation according to Claim 5
for use in the treatment and prevention of eye

conditions such as myosis induced by the surgical
treatment of cataracts or by chronic eye inflammation,

or in the treatment of pathological conditions of other
sensory organs in which gastrin, cholecystokinin or

other related biologically active peptides have
physiological or pathological activity.
A pharmaceutical preparation according to Claim 5
for use in the treatment of conditions of the

urino-genital system such as urinary incontinence,
neurogenic bladder, urinary calculus and painful

spastic conditions of the vesico-ureteral and uterine
musculature in general. 
A pharmaceutical preparation according to Claim 5
also comprising pharmaceutically acceptable inactive

ingredients selected from the group consisting of
vehicles, binders, flavourings, dispersants,

preservatives, humectants and mixtures thereof.
A method of preparing a derivative of formula (I)
in which r, t, R
1
, R
2
, R
3
, A and W have the meanings
given in Claim 1 and in which the substituents at the

chiral centre [marked with an asterisk in formula (I)]
have the (R,S), R or S conformation, consisting of

reacting acid derivatives of formula (II):


in which r, R
1
 and R
2
 have the meanings given above,
with suitable amines of formula (III):



in which R
3
, t, A and W have the meanings given in
Claim 1, in a molar ratio of from 1 to 3 at a

temperature of between -15°C and +20°C by the mixed
anhydride method or by other equivalent conventional

methods of synthesis, and in recovering the basic
compounds (I) from the reaction mass either as such or

by salification carried out in an inert solvent by
suitable pharmaceutically-acceptable organic or

inorganic acids.
</CLAIMS>
</TEXT>
</DOC>
